Pamrevlumab

DRUG8 trials

Sponsors

FibroGen, Kyntra Bio, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Conditions

COVID-19COVID-19 PneumoniaCOVID-19 Respiratory InfectionCovid19Duchenne Muscular DystrophyIdiopathic Pulmonary Fibrosis

Phase 2

Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

CompletedNCT01890265

FibroGenIdiopathic Pulmonary Fibrosis

Start: 2013-07-30End: 2017-11-16Updated: 2020-09-04

Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

TerminatedNCT02606136

Kyntra BioDuchenne Muscular Dystrophy

Start: 2016-01-04End: 2023-08-09Updated: 2024-08-27

Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease

TerminatedNCT04432298

Kyntra BioCOVID-19

Start: 2020-06-20End: 2021-03-22Updated: 2022-07-18

An Open-label, Randomized, Parallel-arm Study Investigating the Efficacy and Safety of Intravenous Administration of Pamrevlumab Versus Standard of Care in Patients With COVID-19

CompletedNCT05262309

Fondazione Policlinico Universitario Agostino Gemelli IRCCSCovid19, COVID-19 Pneumonia, COVID-19 Respiratory Infection

Start: 2020-05-12End: 2022-01-01Updated: 2022-03-02

Phase 3

Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

TerminatedNCT03955146

FibroGenIdiopathic Pulmonary Fibrosis

Start: 2019-06-18End: 2023-08-28Updated: 2024-09-19

Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)

TerminatedNCT04371666

FibroGenDuchenne Muscular Dystrophy

Start: 2020-08-10End: 2023-08-17Updated: 2024-03-12

Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

TerminatedNCT04419558

Kyntra BioIdiopathic Pulmonary Fibrosis

Start: 2020-09-30End: 2023-09-04Updated: 2024-08-12

Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD

TerminatedNCT04632940

Kyntra BioDuchenne Muscular Dystrophy

Start: 2021-03-03End: 2023-12-14Updated: 2024-08-26

Related Papers

Minimum clinically important difference in Quantitative Lung Fibrosis score associated with all-cause mortality in idiopathic pulmonary fibrosis: subanalysis from two phase II trials of pamrevlumab

BMJ Open2025-05-01

Pamrevlumab for Idiopathic Pulmonary Fibrosis

JAMA2024-05-1944 citations

A formula for predicting emphysema extent in combined idiopathic pulmonary fibrosis and emphysema.

2024-01-182 citations

An adjudication algorithm for respiratory-related hospitalisation in idiopathic pulmonary fibrosis

ERJ Open Research2024-01-013 citations

Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular Dystrophy

Journal of Neuromuscular Diseases2023-05-2419 citations

Antibodies to watch in 2020.

2020-01-01328 citations

Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.

2019-09-28212 citations

PRAISE IPF study correlation between quantitative lung fibrosis (QLF) measured by quantitative high resolution computed tomography (qHRCT) and quality of life (QoL) assessed by St. George’s respiratory questionnaire (SGRQ)

2019-09-281 citations